MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma

Histopathology

Volumn 68, Issue 3, 2016, Pages 442-449

  Choe, Ji Young ^a,b   Yun, Ji Yun ^a,b   Na, Hee Young ^b,c   Huh, Jooryung ^d   Shin, Su Jin ^d   Kim, Hyun Jung ^e   Paik, Jin Ho ^a   Kim, Young A ^f   Nam, Soo Jeong ^c   Jeon, Yoon Kyung ^c   Park, Gyeongsin ^g   Kim, Ji Eun ^b,f  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Asan Medical Center   (South Korea)

^e Inha University Hospital   (South Korea)

^f Seoul National University Boramae Hospital   (South Korea)

^g The Catholic University of Korea   (South Korea)

Author keywords

Amplification; Ki67; Mantle cell lymphoma; MYC gene; MYC protein; P53; Prognosis; Translocation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; PREDNISONE; PROTEIN P53; RITUXIMAB; VINCRISTINE; MYC PROTEIN; MYC PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHROMOSOME ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VERY ELDERLY; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84953839202     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12760     Document Type: Article

References (17)

1. Swerdlow S, Campo E, Harris NL et al. eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissue. 4th ed. Lyon: IARC Press, 2008.
2. Dreyling M, Kluin-Nelemans HC, Bea S et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk. Lymphoma 2013; 54; 699-707.
3. Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Bea S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin. Cancer Biol. 2011; 21; 322-334.
4. Setoodeh R, Schwartz S, Papenhausen P et al. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int. J. Clin. Exp. Pathol. 2013; 6; 155-167.
5. Sewastianik T, Prochorec-Sobieszek M, Chapuy B, Juszczynski P. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochim. Biophys. Acta 2014; 1846; 457-467.
6. Aukema SM, Siebert R, Schuuring E et al. Double-hit B-cell lymphomas. Blood 2011; 117; 2319-2331.
7. Durot E, Patey M, Luquet I, Gaillard B, Kolb B, Delmer A. An aggressive B-cell lymphoma with rearrangements of MYC and CCND1 genes: a rare subtype of double-hit lymphoma. Leuk. Lymphoma 2013; 54; 649-652.
8. Delas A, Sophie D, Brousset P, Laurent C. Unusual concomitant rearrangements of cyclin D1 and MYC genes in blastoid variant of mantle cell lymphoma: case report and review of literature. Pathol. Res. Pract. 2013; 209; 115-119.
9. Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am. J. Surg. Pathol. 2015; 39; 294-303.
10. Smith SM, Anastasi J, Cohen KS, Godley LA. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol. Dis. 2010; 45; 317-323.
11. Barrans S, Crouch S, Smith A et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J. Clin. Oncol. 2010; 28; 3360-3365.
12. Mossafa H, Damotte D, Jenabian A et al. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk. Lymphoma 2006; 47; 1885-1893.
13. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood 2013; 122; 3884-3891.
14. Oberley MJ, Rajguru SA, Zhang C et al. Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology 2013; 63; 499-508.
15. Vose JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 2013; 88; 1082-1088.
16. Nordstrom L, Sernbo S, Eden P et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma-a Nordic Lymphoma Group study. Br. J. Haematol. 2014; 166; 98-108.
17. Stefancikova L, Moulis M, Fabian P et al. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int. J. Oncol. 2010; 36; 699-706.